Overall market sentiment has been down on Morphosys Ag (MOR) stock lately. MOR receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.
Morphosys Ag has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on MOR!
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With MOR Stock Today?
Morphosys Ag (MOR) stock is trading at $4.39 as of 10:03 AM on Tuesday, Sep 27, a gain of $0.02, or 0.46% from the previous closing price of $4.37. The stock has traded between $4.36 and $4.46 so far today. Volume today is low. So far 7,969 shares have traded compared to average volume of 49,235 shares.
To screen for more stocks like Morphosys Ag click here.
More About Morphosys Ag
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.
Click Here to get the full Stock Report for Morphosys Ag stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
